CAN10 Counters Scleroderma Development in Preclinical Study
Cantargia’s investigational antibody treatment, CAN10, showed promise in an animal model of systemic sclerosis (or scleroderma), normalizing several biological indicators of disease and counteracting disease development in the skin and lungs. “We are excited about these new results, showing strong effects of CAN10 in a systemic sclerosis model.